Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.62 |
| ▸ | NPC1 | O15118 | 14/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.62 |
| ▸ | TP53 | P04637 | 5/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.62 |
| ▸ | RELA | Q04206 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27520204 | 0.86 | NPC1 (0.53) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL5679468 | 0.86 | FLT3 (0.51) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL14499185 | 0.85 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL5896838 | 0.84 | FLT3 (0.49) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL8210586 | 0.84 | SMAD3 (0.51) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL7470087 | 0.83 | PDGFRB (0.60) | RAB9ANPC1SMN1; SMN2TP53KMT2A | |
| SCHEMBL7469267 | 0.83 | PDGFRB (0.57) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL8695258 | 0.83 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL8693183 | 0.83 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL5675864 | 0.82 | MMP2 (0.51) | RAB9ANPC1SMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320522-B8 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | LEE MOSES (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1320522-B1 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-6660742-B2 | Alkylation therapy; anticancer agent | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| EP-1320522-A2 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | MEDIMMUNE LIMITED (GB) | 2003-04-17 | — | — | US | disclosed |
| EP-0656360-B1 | TRIFLUOROMETHYLPYRROLOINDOLE CARBOXYLIC ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KYORIN SEIYAKU KK (JP) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002030894-A2 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-18 | — | — | WO | disclosed |
| EP-0680964-B1 | PYRROLO [3,2-e]INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE | UNIV SANTIAGO COMPOSTELA (ES) | 2002-01-16 | — | — | EP | disclosed |
| US-6130237-A | Condensed N-aclyindoles as antitumor agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-10 | — | — | US | disclosed |
| EP-0938474-A2 | CYCLOPROPYLINDOLE COMPOUNDS AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-09-01 | — | — | EP | disclosed |
| US-5786377-A | ANTITUMOR AGENTS; ANTICANCER AGENTS | UNIVERSIDAD DE SANTIAGO DE COMPOSTELA (ES) | 1998-07-28 | — | — | US | disclosed |
| WO-1998011101-A2 | CONDENSED N-ACLYINDOLES AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| US-5629430-A | ANTICARCINOGENIC AGENTS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0680964-A1 | NEW PIRROLO 3,2-e]INDOL DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND APPLICATIONS | UNIVERSIDAD DE SANTIAGO DE COMPOSTELA (ES) | 1995-11-08 | — | — | EP | disclosed |
| EP-0656360-A1 | TRIFLUOROMETHYLPYRROLOINDOLE CARBOXYLIC ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | DDB1, ERCC2, SSU72 | RAB9A 3639/4885NPC1 2541/4885SMN1; SMN2 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.